Sam Chun Dang Pharm. Co.,Ltd completed the acquisition of 61.27% stake in DHP Korea Ltd.
December 26, 2012 at 11:00 pm EST
Share
Sam Chun Dang Pharm. Co.,Ltd (KOSE:A000250) agreed to acquire 61.27% stake in DHP Korea Ltd. for approximately KRW 14 billion on December 26, 2012. Sam Chun will acquire 2.14 million shares of DHP Korea. DHP Korea reported sales of KRW 16.64 billion, net income of KRW 552.01 million, total assets of KRW 27.48 billion and total shareholders' equity of KRW 7.7 billion for the year ending December 31, 2011. Board of Directors of Sam Chun Dang Pharm passed resolution as on December 26, 2012. Transaction is expected to close on December 27, 2012.
Sam Chun Dang Pharm. Co.,Ltd (KOSE:A000250) completed the acquisition of 61.27% stake in DHP Korea Ltd. on December 27, 2012.
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.